Neovasc Reducer Featured in Peer Reviewed EuroIntervention and PCR Online
Vancouver, British Columbia--(Newsfile Corp. - March 3, 2020) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and minimally invasive devices for the treatment of refractory angina, announced today the Neovasc Reducer™ (the "Reducer") was featured in the peer reviewed publication EuroIntervention, the official Journal of EuroPCR and the European Association of...
2020-03-03 9:00 AM EST
Neovasc Will Request Nasdaq Hearing After Company Received Expected Delisting Determination From Nasdaq Staff
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - February 20, 2020) - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that it will request a hearing before the Nasdaq Hearings Panel (the "Panel") as the next step in the process in seeking an...
2020-02-20 6:45 AM EST
Neovasc to Participate in SVB Leerink 9th Annual Global Healthcare Conference on February 26, 2020
Vancouver, British Columbia--(Newsfile Corp. - February 18, 2020) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that Fred Colen, CEO of Neovasc, will be participating in the SVB Leerink 9th Annual Global Healthcare Conference on Wednesday, February 26, 2020...
2020-02-18 9:00 AM EST
Neovasc Achieves Design Freeze for Transfemoral Trans-septal Tiara(TM) Mitral Valve System
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - February 12, 2020) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today achievement of design freeze for its fully retrievable transfemoral trans-septal Tiara™ ("TF/TS Tiara") system, including a...
2020-02-12 9:30 AM EST
Neovasc Initiates Independent Inquiry into Trading of Its Shares
Vancouver, British Columbia--(Newsfile Corp. - February 11, 2020) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that the Company has retained independent expert Joshua Mitts, a professor at Columbia University specializing in securities trading and the...
2020-02-11 7:30 AM EST
Neovasc Provides Update on Nasdaq Compliance
Vancouver, British Columbia--(Newsfile Corp. - February 3, 2020) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today confirms that the Company fell below the Nasdaq's minimum market value of listed securities ("MVLS") threshold of $35 million on January 31, 2020. The MVLS...
2020-02-03 7:30 AM EST
Neovasc Announces Renewal of German Reimbursement NUB Status 1 Designation for Neovasc Reducer(TM) for Treatment of Refractory Angina
Vancouver, British Columbia--(Newsfile Corp. - January 31, 2020) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that the Institut für das Entgeltsystem im Krankenhaus ("InEK"), (the German Institute for the Hospital Remuneration System), has awarded the...
2020-01-31 9:00 AM EST
Neovasc Announces Executive Steering Committee for Transfemoral Trans-Septal Tiara Program
Vancouver, British Columbia--(Newsfile Corp. - January 28, 2020) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today the Executive Steering Committee for its fully retrievable transfemoral trans-septal Tiara™ ("TF/TS Tiara") program. The Company intends to enroll...
2020-01-28 9:00 AM EST
Neovasc Advances New Transfemoral Trans-Septal Tiara Design Concept After Further Successful Tests
Vancouver, British Columbia--(Newsfile Corp. - January 24, 2020) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that after further successful acute animal tests conducted earlier this week, a final design concept for the fully retrievable transfemoral...
2020-01-24 9:00 AM EST
Neovasc Reducer(TM) for Treatment of Refractory Angina Featured in Multiple Presentations in Germany
Vancouver, British Columbia--(Newsfile Corp. - January 22, 2020) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that the Neovasc Reducer™ ("Reducer") was featured in three presentations across Germany this month.The presentations included:At the 20th...
2020-01-22 9:00 AM EST
Updates on Reducer and Tiara Programs Will be Presented at Advanced Cardiovascular Intervention 2020 Meeting
Vancouver, British Columbia--(Newsfile Corp. - January 21, 2020) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that Clinicians will provide an update on its Neovasc Reducer™ ("Reducer") as well as on its Tiara™ ("Tiara") mitral valve program, including its...
2020-01-21 9:00 AM EST
Neovasc Receives Administrative Acceptance Review Notification for Premarket Approval Application from FDA for the Neovasc Reducer(TM)
Vancouver, British Columbia--(Newsfile Corp. - January 15, 2020) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") , a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced receipt of an Administrative Acceptance Review Notification for the Company's Premarket Approval application ("PMA") from the U.S. Food and Drug...
2020-01-15 7:00 AM EST
Neovasc Inc. Investor Update
Vancouver, British Columbia--(Newsfile Corp. - January 13, 2020) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, seeks to provide an update for investors, including a recap of recent corporate activity and a look ahead into 2020 in advance of the J.P. Morgan Investor...
2020-01-13 7:00 AM EST
Neovasc Announces Closing of $10 Million Registered Direct Offering Priced At-The-Market
Vancouver, British Columbia--(Newsfile Corp. - January 6, 2020) - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVCN) announced today that it has closed its previously announced registered direct offering (the "Offering") priced at-the-market under Nasdaq rules of an aggregate of 1,185,000 series A units ("Series A Units") and 1,241,490 series B units ("Series B Units" and together with the Series A Units, the "Units") at a price of US$4.1351 per Series A Unit and US$4.135...
2020-01-06 3:03 PM EST
Neovasc Announces $10 Million Registered Direct Offering Priced At-The-Market
Vancouver, British Columbia--(Newsfile Corp. - January 2, 2020) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced today that it has entered into definitive agreements with certain institutional investors for the sale of an aggregate of 2,418,322 series A units ("Series A Units") and series B units ("Series B Units" and together with the Series A Units, the "Units") at a price of US$4.1351 per Series A Unit and US$4.135 per Series B Unit in a registered...
2020-01-02 8:17 AM EST
Neovasc Submits Premarket Approval Application to FDA for Neovasc Reducer(TM)
Vancouver, British Columbia--(Newsfile Corp. - December 31, 2019) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced the submission of a Premarket Approval application ("PMA") to the U.S. Food and Drug Administration ("FDA") for its Neovasc Reducer™ ("Reducer")...
2019-12-31 7:00 AM EST
Neovasc Reducer(TM) Featured In National Geographic Magazine
Vancouver, British Columbia--(Newsfile Corp. - December 17, 2019) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that the Neovasc Reducer™ (the "Reducer") was featured in a special issue titled: "The Future of Medicine" of National Graphic Magazine, published...
2019-12-17 7:00 AM EST
Neovasc Named Finalist in Questex's Fierce Innovation Awards Lifesciences Edition 2019
Vancouver, British Columbia--(Newsfile Corp. - December 4, 2019) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that it has been selected as a finalist in this year's Fierce Innovation Awards - LifeSciences Edition, a peer reviewed awards program from the...
2019-12-04 9:58 AM EST
Neovasc Reducer(TM) Featured In FOCUS Magazine
British Columbia and Berlin, Germany--(Newsfile Corp. - November 26, 2019) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that the Neovasc Reducer™ (the "Reducer") was featured in a supplement in the FOCUS Magazine, one of the three most widely circulated...
2019-11-26 7:00 AM EST
Neovasc Reducer(TM) Featured During Therapy Development Program in Coburg and Session at Maria Cecilia Hospital in Cotignola
Cotignola, Italy--(Newsfile Corp. - November 22, 2019) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that the Neovasc Reducer™ (the "Reducer") was featured during a program hosted in Coburg on Wednesday, November 20, 2019. Additionally, on Friday, November...
2019-11-22 7:00 AM EST